Compare MED & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MED | MDWD |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6M | 230.7M |
| IPO Year | N/A | 2014 |
| Metric | MED | MDWD |
|---|---|---|
| Price | $12.33 | $19.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $16.50 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 205.6K | 92.0K |
| Earning Date | 11-03-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $429,695,000.00 | $20,932,000.00 |
| Revenue This Year | N/A | $15.89 |
| Revenue Next Year | N/A | $25.33 |
| P/E Ratio | $592.83 | ★ N/A |
| Revenue Growth | N/A | ★ 6.15 |
| 52 Week Low | $10.36 | $14.14 |
| 52 Week High | $21.98 | $22.51 |
| Indicator | MED | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 66.00 | 59.17 |
| Support Level | $10.72 | $18.71 |
| Resistance Level | $11.12 | $19.63 |
| Average True Range (ATR) | 0.34 | 0.71 |
| MACD | 0.22 | 0.18 |
| Stochastic Oscillator | 98.20 | 76.67 |
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.